Ad
related to: news pfizer
Search results
Pfizer's $1.5B cuts; Biogen's $1.15B buyout; AstraZeneca's $80B ambition; RNA startup merger; and...
Endpoints News· 5 days agoWant this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. Whether you will be in San Diego for BIO, we hope you will join ...
WPP integrates Anthropic’s tech to further generative AI transformation
Marketing Dive via Yahoo Finance· 2 days agoKeeping pace with generative AI is important for WPP as it vies for a turnaround. The group in...
Bird Flu Keeps Spreading in U.S. Cows. 5 Big Questions, Answered.
Barrons.com· 2 days agoThe CDC said this week that O’Connell’s agency is planning more studies to begin late this summer....
Innovative cancer therapies offer new hope
Nature· 1 day agoThe arsenal of weapons used to treat these insidious diseases is rapidly expanding.
1 High-Yield ETF Could Turn $400 Per Month Into $50,000 In Annual Dividend Income | The Motley Fool
The Motley Fool· 4 days agoBuilding a portfolio of dividend stocks that can replace all or some of your paycheck is a big goal...
Is Vaginal Estrogen Safe in Breast Cancer Survivors?
Medscape· 7 days agoVaginal estrogen therapy appears to be safe after early breast cancer in patients with HR-negative tumors and those with HR-positive tumors concurrently...
The bird flu vaccine is made with eggs. That has scientists worried.
CBS News· 19 hours ago"It's almost comical to be using a 1940s technology for a 21st-century pandemic," said Rick Bright,...
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
Zacks· 23 hours agoExact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.
Ignoring Colonoscopy Advice; Inflamed Tongue, Then Cancer; Acupuncture for Dry Mouth
MedPage Today· 6 days agoNews, features, and commentary about cancer-related issues
Feds plan for smoother access to RSV infant shot
Politico· 12 hours agoJohnson & Johnson struck a deal to buy an experimental skin disease drug for $1.25 billion, BioPharma Dive’s Ben Fidler reports. The FDA issued a priority review voucher to Pfizer< ...